714 related articles for article (PubMed ID: 33293694)
21. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells.
Geng R; Tan X; Zuo Z; Wu J; Pan Z; Shi W; Liu R; Yao C; Wang G; Lin J; Qiu L; Huang W; Chen S
Chin J Cancer; 2017 Jul; 36(1):63. PubMed ID: 28756770
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
Zhang B; Lyu J; Liu Y; Wu C; Yang EJ; Pardeshi L; Tan K; Wong KH; Chen Q; Xu X; Deng CX; Shim JS
Oncogene; 2018 Dec; 37(49):6341-6356. PubMed ID: 30042414
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.
Yang J; Cao C; Luo D; Lan S; Luo M; Shan H; Ma X; Liu Y; Yu S; Zhong X; Li R
Eur J Med Chem; 2020 Jul; 198():112336. PubMed ID: 32387836
[TBL] [Abstract][Full Text] [Related]
24. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc.
Gao FH; Hu XH; Li W; Liu H; Zhang YJ; Guo ZY; Xu MH; Wang ST; Jiang B; Liu F; Zhao YZ; Fang Y; Chen FY; Wu YL
BMC Cancer; 2010 Nov; 10():610. PubMed ID: 21054888
[TBL] [Abstract][Full Text] [Related]
25. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
Damaneh MS; Hu JP; Huan XJ; Song SS; Tian CQ; Chen DQ; Meng T; Chen YL; Shen JK; Xiong B; Miao ZH; Wang YQ
Invest New Drugs; 2020 Jun; 38(3):700-713. PubMed ID: 31267379
[TBL] [Abstract][Full Text] [Related]
26. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
[TBL] [Abstract][Full Text] [Related]
27. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
28. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
29. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
30. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
[TBL] [Abstract][Full Text] [Related]
32. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
33. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
34. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
35. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer.
Kwak B; Kim DU; Kim TO; Kim HS; Kim SW
Int J Oncol; 2018 Oct; 53(4):1800-1808. PubMed ID: 30066856
[TBL] [Abstract][Full Text] [Related]
37. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
38. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
39. Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer.
Hashimoto M; Masuda T; Nakano Y; Tobo T; Saito H; Koike K; Takahashi J; Abe T; Ando Y; Ozato Y; Hosoda K; Higuchi S; Hisamatsu Y; Toshima T; Yonemura Y; Hata T; Uemura M; Eguchi H; Doki Y; Mori M; Mimori K
Cancer Sci; 2024 Jun; 115(6):1866-1880. PubMed ID: 38494600
[TBL] [Abstract][Full Text] [Related]
40. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]